Clinical Marker, Ovarian Cancer, PARP Inhibitor
Conditions
Keywords
Ovarian caner, PARP inhibitor, Clinical marker
Brief summary
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. PARP inhibitors(PARPi) are an important progress in EOC treatment. The available evidence suggests that BRCAmt or HRD-positive is an effective biological marker for PARPi. However, in our previous clinical observation, it was found that the tumor burden may be the potential clinical markers PARPi. We intend to develop a real-world study to confirm the potential clinical markers and explore new clinical markers for PARPi.
Detailed description
This study intends to conduct a systematic real-world study to observe the relationship between the clinical characteristics of EOC patients and the efficacy of PARPi based on our existing research foundation and stratified analyse these correlations by BRCA and HRD status.
Interventions
DRUGPARP inhibitors
Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.
Sponsors
Xiaoxiang Chen
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects join the study voluntarily and sign informed consent; 2. Female subjects are older than 18 years; 3. ECOG(Eastern Cooperative Oncology Group) physical status score is 0-2; 4. Life expectancy≥3 months; 5. Histologically confirmed FIGO(International Federation of Gynecology and Obstetrics ) III/IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; Participants must have high-grade serous or endometrioid histology; 6. Patients should test for BRCA gene and will perform test for HRD status if who harbor BRCAwt in the same laboratory designated by the researcher; 7. Patients received PARP inhibitor as maintenance therapy or monotherapy for more than four weeks.
Exclusion criteria
1. Personnel involved in the formulation or implementation of the research plan; 2. Patient participated in other clinical trails using other experimental drugs at the same time as the study; 3. The subjects had other malignant diseases in past 2 years, except skin squamous cell carcinoma, basal-like carcinoma, breast intraductal carcinoma in situ, or cervical carcinoma in situ; 4. Previous or currently diagnosed myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML); 5. Patients who are pregnant or lactation, or who plan to become pregnant during study treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | Through study completion, an average of 1 year | ORR is defined as the proportion of participants achieving complete response (CR) or partial response (PR) as assessed by RECIST1.1. |
| Progression Free Survival (PFS) | Through study completion, an average of 1 year | PFS is defined as the time in months from the date of first study drug administration to the date of first documentation of progressive disease (PD) or death as assessed by RECIST1.1. |
| Duration of Response (DOR) | Through study completion, an average of 1 year | DOR is defined as the time from the first date of response until the date of first documented progression. |
| Disease Control Rate (DCR) | Through study completion, an average of 1 year | DCR is defined as the proportion of participants achieving complete response (CR), partial response (PR) or stable disease (SD) according to RECIST1.1. |
| Adverse events (AEs) | Through study completion, an average of 1 year | Number of participants with treatment-related adverse events as assessed by CTCAE 5.0 to further describe safety and assess toxicities encountered with the use of the proposed treatment regimen in participants. |
Countries
China
Contacts
Primary ContactJing Ni, MD
Outcome results
None listed